<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196816</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL19_0534</org_study_id>
    <nct_id>NCT04196816</nct_id>
  </id_info>
  <brief_title>Surgery for Pancreatic Cancer With Oligo-Metastasis</brief_title>
  <acronym>SPaM</acronym>
  <official_title>Surgery/Destruction for Stage IV Pancreatic Cancer With Oligo-Metastatic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Digestive Surgery and Transplantation, Université de Montpellier- Nîmes, Montpellier, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Association de Chirurgie hepato-bilio-pancreatique et transplantation (ACHBT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federation de recherche en chirurgie digestive (FRENCH)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Club Français du Pancreas (CFP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic cancer is increasing in incidence and will be the second leading cause of
      cancer-related deaths in 2030 in the West. Only 10 to 15% of patients are eligible for
      curative resection with long-term survival rarely exceeding 20% at 5 years. The management of
      metastatic or recurrent diseases can not, unfortunately, be recommended to date because of
      limited data available (INCA 2019).

      However, recent, low-strength publications have reported encouraging results on the long-term
      survival of stage IV or recurrent patients.

      The aim of the present retrospective cohort study is to analyze results of
      surgery/destruction of metastatic synchronous or metachronous disease or local recurrence in
      patients with stage IV pancreatic cancer
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival at 3 years (percentage of patients alive). Overall survival (OS) (time from diagnosis until death, regardless of cause)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Progression-free survival (percentage of patients without recurrence) at 3 years. Progression-free survival (PFS) (time from diagnosis to time of first radiological evidence of local, regional, or distant relapse, or death due to any cause)</description>
  </secondary_outcome>
  <enrollment type="Actual">200</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Pancreatic Surgery</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who had resection or destruction of one or more synchronous or metachronous
        metastases or local recurrence of pancreatic adenocarcinoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

        - Patients who had resection or destruction of one or more synchronous or metachronous
        metastases or local recurrence of pancreatic adenocarcinoma

        Details:

          -  synchronous lesions, metachrones can be included

          -  all distant lesions (hepatic, pulmonary) can be included

          -  documented lymph node involvement after analysis of the specimen (hepatic hilum,
             mesenteric root, retroperitoneal or inter-aortic-cellar) can be included

          -  patients with local recurrence who underwent surgical treatment

        Exclusion Criteria:

        - Patient who reject the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>REGIS SOUCHE</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Surgery</keyword>
  <keyword>Metastasis surgery</keyword>
  <keyword>Survival</keyword>
  <keyword>Multimodal treatment</keyword>
  <keyword>Stage IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

